Joining On Focus today is Stuart McIntyre, Director of Marketing & Business Development at AngioDynamics, developer of a new approach to focal therapy called NanoKnife. It is currently running a clinical trial called PRESERVE, described as a Pivotal Study of the NanoKnife System for Ablation of Prostate Tissue in an Intermediate-Risk Patient Population and which will evaluate the use of AngioDynamics’ NanoKnife System for ablation of prostate tissue as a focal therapy option for prostate cancer patients.

Stuart’s here to talk about how his company developed the NanoKnife system and what his expectations are for its adoption.

PRESERVE trial

https://www.angiodynamics.com/announcements/first-patients-treated-in-preserve-clinical-study/